Table 5 Medications use in 2 years by gender, age and migraine status
| Â | ACUTE | PREVENTIVE | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gender | N. | Triptans | NSAIDs | Combination analgesics | Opioids | Simple analgesics | Antidepressants | β-blockers | Angiotensin inhibitors | OnabotulinumtoxinA | Calcium channel blockers | Nutraceutics | Anxiolytics | Antiepileptics |
Men | 80 | 44 (55) | 37 (46.3) | 45 (56.3) | 2 (2.5) | 2 (2.5) | 25 (31.3) | 15 (18.8) | 3 (3.8) | 45 (56.3) | 44 (55) | 43 (53.8) | 15 (18.8) | 6 (7.5) |
Women | 468 | 309 (66) | 243 (51.9) | 231 (49.4) | 3 (0.6) | 34 (7.3) | 171 (36.5) | 49 (10.5) | 15 (3.2) | 314 (67.1) | 312 (66.7) | 311 (66.5) | 106 (22.6) | 74 (15.8) |
p-value | NS | NS | NS | NS | NS | NS | 0.003 | NS | NS | 0.043 | 0.028 | NS | NS | |
Age | N. | Triptans | NSAIDs | Combination analgesics | Opioids | Simple analgesics | Antidepressants | β-blockers | Angiotensin inhibitors | OnabotulinumtoxinA | Calcium channel blockers | Nutraceutics | Anxiolytics | Antiepileptics |
18-34 | 57 | 44 (77.2) | 34 (59.6) | 35 (61.4) | 0 (0) | 2 (3.5) | 10 (17.5) | 1 (1.8) | 0 (0) | 25 (43.9) | 34 (59.6) | 43 (75.4) | 6 (10.5) | 7 (12.3) |
35-44 | 63 | 50 (79.4) | 32 (50.8) | 38 (60.3) | 2 (3.2) | 3 (4.8) | 25 (39.7) | 4 (6.3) | 0 (0) | 43 (68.3) | 49 (77.8) | 44 (69.8) | 12 (19) | 7 (11.1) |
45-54 | 196 | 144 (73.5) | 97 (49.5) | 94 (48) | 1 (0.5) | 7 (3.6) | 70 (35.7) | 30 (15.3) | 7 (3.6) | 125 (63.8) | 129 (65.8) | 141 (71.9) | 42 (21.4) | 31 (15.8) |
55-64 | 155 | 92 (59.4) | 79 (51) | 70 (45.2) | 2 (1.3) | 12 (7.7) | 53 (34.2) | 22 (14.2) | 5 (3.2) | 113 (72.9) | 92 (59.4) | 91 (58.7) | 42 (27.1) | 20 (12.9) |
> 65 | 77 | 23 (29.9) | 38 (49.4) | 39 (50.6) | 0 (0) | 12 (15.6) | 38 (49.4) | 7 (9.1) | 6 (7.8) | 53 (68.8) | 52 (67.5) | 35 (45.5) | 19 (24.7) | 15 (19.5) |
p-value | < 0.0001 | NS | NS | NS | 0.011 | 0.005 | 0.016 | NS | 0.003 | NS | < 0.0001 | NS | NS | |
Diagnosis | N. | Triptans | NSAIDs | Combination analgesics | Opioids | Simple analgesics | Antidepressants | β-blockers | Angiotensin inhibitors | OnabotulinumtoxinA | Calcium channel blockers | Nutraceutics | Anxiolytics | Antiepileptics |
CM | 359 | 220 (61.3) | 207 (57.7) | 151 (42.1) | 4 (1.1) | 30 (8.4) | 149 (41.5) | 45 (12.5) | 15 (4.2) | 359 (100) | 230 (64.1) | 200 (55.7) | 107 (29.8) | 60 (16.7) |
EM | 189 | 133 (70.4) | 73 (38.6) | 125 (66.1) | 1 (0.5) | 6 (3.2) | 47 (24.9) | 19 (10.1) | 3 (1.6) | 0 (0) | 126 (66.7) | 154 (81.5) | 14 (7.4) | 20 (10.6) |
p-value | 0.035 | < 0.0001 | < 0.0001 | NS | 0.020 | 0.000 | NS | NS | < 0.0001 | NS | < 0.0001 | < 0.0001 | NS | |
Total | 548 | 353 (64.4) | 280 (51.1) | 276 (50.4) | 5 (0.9) | 36 (6.6) | 196 (35.8) | 64 (11.7) | 18 (3.3) | 359 (65.5) | 356 (65) | 354 (64.6) | 121 (22.1) | 80 (14.6) |